Biopharm GmbH

BIOPHARM is one of the pioneers in the research and development of biologics. Our platform technology of recombinant
human growth factors combines our expertise and experience of more than 30 years with innovative applications in the
field of orthopedics, dermatology and personalized medicine. BIOPHARM successfully achieved Proof of Concept for all
indications and is now out-licensing the product pipeline for further clinical development and commercialization.


Our mission is driven by our company philosophy of constant innovation. Combining our expertise and experience of more than 30 years in Biotechnology BIOPHARM is devoted to discovering innovative substances and technologies in Regenerative Medicine. As a privately-owned company we strive to maintain independence and flexibility. Our core values are committed to improve human life, achieve scientific excellence and operate with the highest standards of integrity to meet the changing needs of the health
care market worldwide.


Michael Paulista Michael Paulista – Managing Director Michael founded Biopharm 1986 in the growing biotech ecosystem of Heidelberg, Germany. Since, he has succeeded to create a Growth Factor Platform Technology around the proprietary growth factor GDF-5. He has developed several partnerships and licenses with big pharma companies.


Knee osteoarthritis has been designated a ‘priority disease’ by the World Health Organization, being one of the ten most disabling diseases in developed countries.

One of the few genes associated with osteoarthritis is the Growth and Differentiation Factor 5 (GDF5), a protein of the Bone Morphogenetic Protein (BMP) family. Biopharm GmbH has developed the highly effective variant R399E, a single point mutation of GDF5. Preclinical osteoarthritis development performed by Merck KGaA exhibits a unique combination of anabolic, anti-catabolic, anti-inflammatory and pain-reducing properties for R399E.

Currently, Biopharm GmbH owns all rights on R399E after the decision of Merck KGaA to exit osteoarthritis development focusing now on other strategic indications. This creates the unique opportunity to invest into a phase 1 ready, “pharma-grade” development candidate. R399E has the chance to become a prominent acquisition target for pharma companies to enter financially attractive osteoarthritis market.


Show publications


BIOPHARM is located in Eppelheim near Heidelberg in the centre of the Rhine-Neckar Region.